Patents by Inventor Shigeru Shioya

Shigeru Shioya has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antidiabetic preparation for oral administration
    Patent number: 7488498
    Abstract: There is provided a single preparation which directly decreases both of the post prandial blood glucose level and the fasting blood glucose level close to normal levels, by release-sustaining a drug capable of decreasing the post prandial blood glucose level of diabetic patients close to the normal level, or mixing a controlled release drug capable of decreasing the post prandial blood glucose level close to the normal level with an immediate release drug. It is particularly preferable that the drug capable of decreasing the post prandial blood glucose level close to the normal level is nateglinide.
    Type: Grant
    Filed: October 11, 2005
    Date of Patent: February 10, 2009
    Assignee: Ajinomoto Co., Inc.
    Inventors: Chisato Makino, Nobutaka Ninomiya, Haruo Orita, Hidetoshi Sakai, Akira Yabuki, Nobuo Kato, Shigeru Shioya
  • Antidiabetic preparation for oral administration
    Patent number: 7022339
    Abstract: There is provided a single preparation which directly decreases both of the post prandial blood glucose level and the fasting blood glucose level close to normal levels, by release-sustaining a drug capable of decreasing the post prandial blood glucose level of diabetic patients close to the normal level, or mixing a controlled release drug capable of decreasing the post prandial blood glucose level close to the normal level with an immediate release drug. It is particularly preferable that the drug capable of decreasing the post prandial blood glucose level close to the normal level is nateglinide.
    Type: Grant
    Filed: June 28, 2002
    Date of Patent: April 4, 2006
    Assignee: Ajinomoto Co., Inc.
    Inventors: Chisato Makino, Nobutaka Ninomiya, Haruo Orita, Hidetoshi Sakai, Akira Yabuki, Nobuo Kato, Shigeru Shioya
  • Antidiabetic preparation for oral administration
    Publication number: 20060029669
    Abstract: There is provided a single preparation which directly decreases both of the post prandial blood glucose level and the fasting blood glucose level close to normal levels, by release-sustaining a drug capable of decreasing the post prandial blood glucose level of diabetic patients close to the normal level, or mixing a controlled release drug capable of decreasing the post prandial blood glucose level close to the normal level with an immediate release drug. It is particularly preferable that the drug capable of decreasing the post prandial blood glucose level close to the normal level is nateglinide.
    Type: Application
    Filed: October 11, 2005
    Publication date: February 9, 2006
    Applicant: Ajinomoto Co., Inc.
    Inventors: Chisato Makino, Nobutaka Ninomiya, Haruo Orita, Hidetoshi Sakai, Akira Yabuki, Nobuo Kato, Shigeru Shioya
  • Antidiabetic preparation for oral administration
    Patent number: 6830759
    Abstract: There is provided a single preparation which directly decreases both of the post prandial blood glucose level and the fasting blood glucose level close to normal levels, by release-sustaining a drug capable of decreasing the post prandial blood glucose level of diabetic patients close to the normal level, or mixing a controlled release drug capable of decreasing the post prandial blood glucose level close to the normal level with an immediate release drug. It is particularly preferable that the drug capable of decreasing the post prandial blood glucose level close to the normal level is nateglinide, repaglinide, or mitiglinide (KAD-1229).
    Type: Grant
    Filed: June 28, 2002
    Date of Patent: December 14, 2004
    Assignee: Ajinomoto Co., Inc.
    Inventors: Chisato Makino, Nobutaka Ninomiya, Haruo Orita, Hidetoshi Sakai, Akira Yabuki, Nobuo Kato, Shigeru Shioya
  • Antidiabetic preparation for oral administration
    Publication number: 20040002544
    Abstract: There is provided a single preparation which directly decreases both of the post prandial blood glucose level and the fasting blood glucose level close to normal levels, by release-sustaining a drug capable of decreasing the post prandial blood glucose level of diabetic patients close to the normal level, or mixing a controlled release drug capable of decreasing the post prandial blood glucose level close to the normal level with an immediate release drug. It is particularly preferable that the drug capable of decreasing the post prandial blood glucose level close to the normal level is nateglinide, repaglinide, or mitiglinide (KAD-1229).
    Type: Application
    Filed: June 28, 2002
    Publication date: January 1, 2004
    Applicant: AJINOMOTO CO. INC
    Inventors: Chisato Makino, Nobutaka Ninomiya, Haruo Orita, Hidetoshi Sakai, Akira Yabuki, Nobuo Kato, Shigeru Shioya
  • Antidiabetic preparation for oral administration
    Publication number: 20030021843
    Abstract: There is provided a single preparation which directly decreases both of the post prandial blood glucose level and the fasting blood glucose level close to normal levels, by release-sustaining a drug capable of decreasing the post prandial blood glucose level of diabetic patients close to the normal level, or mixing a controlled release drug capable of decreasing the post prandial blood glucose level close to the normal level with an immediate release drug. It is particularly preferable that the drug capable of decreasing the post prandial blood glucose level close to the normal level is nateglinide.
    Type: Application
    Filed: June 28, 2002
    Publication date: January 30, 2003
    Applicant: AJINOMOTO CO. INC
    Inventors: Chisato Makino, Nobutaka Ninomiya, Haruo Orita, Hidetoshi Sakai, Akira Yabuki, Nobuo Kato, Shigeru Shioya
  • Method of reducing blood sugar levels using a hypoglycemic agent
    Patent number: 5240911
    Abstract: Pharmaceutical compositions containing the polypeptides BUF-3, BUF-4 and BUF-5 have hypoglycemic activity. BUF-3 is a homodimer of monomer A shown in FIG. 1. The monomer has a molecular weight of 16.+-.1 kd. BUF-4 is a heterodimer of monomer A and monomer B (FIG. 2). These products can be produced by cell culture of malignant leukemia cells or by recombinant DNA engineering.
    Type: Grant
    Filed: September 21, 1989
    Date of Patent: August 31, 1993
    Assignee: Ajinomoto Co., Inc.
    Inventors: Yasuo Totsuka, Itaru Kojima, Etsuro Ogata, Makoto Shiozaki, Shigeru Shioya, Hiroshiro Shibai, Yuzuru Eto